Immune Regulation Limited, a US and UK-based clinical-stage biotechnology company, announced on Monday that it has closed a Series B round of financing led by Boston-based Morningside Ventures, a part of Hong Kong’s Chan family-owned Morningside Group.
Continue reading this premium story with a subscription to DealStreetAsia.Subscribe
Already a Subscriber? Log in
Contact us for corporate subscriptions at email@example.com